[Syncillin in bacterial skin diseases].
A multicentric open clinical trial was carried out by 8 practising specialists in dermatology or paediatrics in patients with bacterial skin diseases who were subjected to a systemic therapy with Syncillin (=Azidocillin). The Syncillin presentation for adults and schoolchildren was tablets of 750 mg each, and sachets of 125 mg or 250 mg for infants. The duration of treatment was 10 days. The parameters analyzed were bacteriological findings and the clinical course of disease. 71 (=74%) of the 96 patients included in this study were considered as cured, 21 (=22%) as improved and 4 patients (=4%) as unchanged. Bacterial identification was still positive in 10 cases after the termination of treatment. However, this did not preclude the assessments of ""cured'' (3 cases) or ""improved'' (7 cases). The tolerance of the preparation was considered as ""very good'' or ""good'' in 91 and as ""poor'' in 5 patients. The most common side effects were nausea and diarrhoea. Exanthema was observed in 2 cases. None of these side effects, however, made a discontinuation of medication necessary. The era of rational and well-directed chemotherapy enables good therapeutic approach also to bacterial skin diseases.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D004341:Drug Evaluation; D006801:Humans; D010400:Penicillin G / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*
D010406:Penicillins; D010400:Penicillin G
Syncillin bei bakteriellen Erkrankungen der Haut